.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Fuji
McKesson
Medtronic
Julphar
Johnson and Johnson
Baxter
Cantor Fitzgerald
Farmers Insurance
Express Scripts

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Sign Up

« Back to Dashboard

Details for Patent: ➤ Sign Up

Title:Modulators of pharmacokinetic properties of therapeutics
Abstract: The present application provides for a compound of Formula I, ##STR00001## or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
Inventor(s): Desai; Manoj C. (Pleasant Hill, CA), Hong; Allen Yu (San Jose, CA), Liu; Hongtao (Cupertino, CA), Vivian; Randall W. (San Mateo, CA), Xu; Lianhong (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Filing Date:Jul 06, 2007
Application Number:11/825,605
Claims:1. A compound of formula IID, ##STR00219## or a pharmaceutically acceptable salt thereof, wherein, L.sup.1 is selected from the group consisting of --C(R.sup.6).sub.2--, --C(O)--, --S(O.sub.2)--, --N(R.sup.7)--C(O)--, and --O--C(O)--; each L.sup.3 is independently a covalent bond, alkylene, or substituted alkylene; each L.sup.4 is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, --O--, --CH.sub.2--O--, and --NH--; each A is independently selected from the group consisting of H, alkyl, substituted alkyl, aryl, substituted aryl, heterocyclyl, and substituted heterocyclyl, with the proviso that when A is H, p is 0; Z.sup.1 and Z.sup.2 are each independently --O-- or --N(R.sup.7)--; Y and X are each independently selected from the group consisting of heterocyclyl and heterocyclylalkyl; each Ar is independently selected from the group consisting of aryl, substituted aryl, heteroaryl, and substituted heteroaryl; R.sup.1, R.sup.3, and R.sup.5 are each independently selected from the group consisting of H, alkyl, substituted alkyl, arylalkyl, and substituted arylalkyl; R.sup.2 is independently selected from the group consisting of H, alkyl, substituted alkyl, alkoxyalkyl, hydroxyalkyl, arylheteroalkyl, substituted arylheteroalkyl, arylalkyl, substituted arylalkyl, heterocyclylalkyl, substituted heterocyclylalkyl, aminoalkyl, substituted aminoalkyl, -alkylene-C(O)--OH, -alkylene-C(O)--Oalkyl, -alkylene-C(O)amino, and -alkylene-C(O)-alkyl; R.sup.4 and R.sup.6 are each independently selected from the group consisting of H, alkyl, substituted alkyl, and heteroalkyl; each R.sup.7 is independently selected from the group consisting of H, alkyl, substituted alkyl, heteroalkyl, carbocyclyl, substituted carbocyclyl, heterocyclyl, and substituted heterocyclyl; R.sup.8 and R.sup.9 are each one or more substituents independently selected from the group consisting of H, alkyl, substituted alkyl, halogen, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, and --CN; and each p is independently 0 or 1.

2. The compound of claim 1, wherein: L.sup.1 is --C(R.sup.6).sub.2--; each L.sup.3 is alkylene; each A is aryl or substituted aryl; X and Y are each heterocyclylalkyl; Z.sup.1 is --N(R.sup.7)--; and Z.sup.2 is --O--.

3. A compound which is: ##STR00220## or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising the compound or salt of formula IID as described in claim 1 and a pharmaceutically acceptable carrier or excipient.

5. The pharmaceutical composition of claim 4, further comprising at least one additional therapeutic agent.

6. The pharmaceutical composition of claim 5, wherein the at least one additional therapeutic agent is metabolized by cytochrome P450 monooxygenase.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Chinese Patent Office
Fuji
Cipla
Medtronic
Moodys
Boehringer Ingelheim
Cerilliant
Citi
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot